Skip to main content

Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one or more phase I trials of various investigational therapies. Patients' tumors or circulating tumor DNA were analyzed by next-generation sequencing. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%. TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, respectively. Alterations in FGFR3 were almost mutually exclusive of TP53. More than half (64%) of patients with an FGFR alt received an FGFR inhibitor, 67% of which achieved disease control. Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter median progression-free survival (PFS) compared with those whose tumors carry wild-type TP53. The reverse relationship was observed in patients harboring an FGFR alteration.

Cite

CITATION STYLE

APA

Alhalabi, O., Hahn, A. W., Msaouel, P., Andreev-Drakhlin, A. Y., Meric-Bernstam, F., Naing, A., … Subbiah, V. (2021). Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Molecular Cancer Research, 19(3), 395–402. https://doi.org/10.1158/1541-7786.MCR-20-0751

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free